2023-09-14 06:46:02 ET
More on Sanofi
- Sanofi: A 'Buy' Recommendation For Undervalued Growth Potential
- Sanofi ( SNY ) Q2 2023 Earnings Call Transcript
- Sanofi 2023 Q2 - Results - Earnings Call Presentation
- Sanofi: Powering Up And Offering Investors A Lot Of Potentials
- Sanofi: EPS Momentum Driven By Dupixent, Vaccines Day On Tap
- Sanofi was mystery suitor in Reata Pharma bidding war - report
- AstraZeneca, Sanofi RSV treatment Beyfortus endorsed by CDC panel (updated)
- Sanofi to grow 'healthy aging' segment with Qunol acquisition
- Sanofi Non-GAAP EPS of €1.74, revenue of €9.96B; raises FY23 guidance
- Sanofi collaborating with Recludix on oral inflammatory disease assets
- Sanofi expands collaboration with Scribe on CRISPR genome editing
For further details see:
Sanofi in licensing pact with First Wave BioPharma for GIT disorder drug